Latest Daily News

Latest News
January 18, 2018

The ASCO-SITC Clinical Immuno-Oncology Symposium Clinical Corner allows expert physicians to answer questions posed by an attendee during previous Best of ASCO Meetings.

Read more
January 18, 2018

Responding to a question from a Best of ASCO Meeting attendee, Dr. Emily Lemke and Dr. Amishi Shah share their preferred immunotherapy for bladder cancer.

Read more
January 18, 2018

Dr. Shailaja Raj and Dr. Pierre Triozzi review the potential of immunotherapy, based on preclinical studies, to treat sarcoma.

Read more
January 18, 2018

Dr. Sandip Patel discusses possible immunotherapeutic treatments for advanced non-small cell lung cancer.

Read more

January 18, 2018

Dr. Ravi Madan and Dr. James Gulley discuss the possible role of immunotherapy in treating prostate cancer.

Read more
January 18, 2018

The incorporation of immunotherapy into the armamentarium of cancer treatments has resulted in significant improvements in outcomes for many patients with advanced cancers. Dr. Robert Chin and Dr. Deborah Wong discuss the benefits of integrating immunotherapy into radiotherapy regimens.

Read more
January 18, 2018

The molecular understanding of T-cell lymphocyte activation and inhibition established the opportunity for cancer immunotherapy.

Read more
January 18, 2018

Dr. Eric D. Whitman answers a question posed by an attendee at a Best of ASCO Meeting.

Read more
January 18, 2018

The most common malignancies that metastasize to the brain are melanoma and non–small cell lung cancer.

Read more
January 18, 2018

Key components for successful management of immune-related adverse events include education, awareness, communication, collaboration, and multidisciplinary care.

Read more

January 18, 2018

Development of therapies for patients with rare tumors can be challenging due to small patient sizes and lack of phase III trials.

Read more

January 18, 2018

Merkel cell carcinoma is characterized by sensitivity to chemotherapy and radiotherapy, but has a high chance of relapse due to distant metastases.

Read more

February 16, 2017

What are the immunotherapy options for patients with melanoma and active autoimmune disease?

Read more

February 16, 2017

Dr. Jeffrey Weber discusses how lessons learned from the use of checkpoint inhibitors in melanoma can be applied to immunotherapy for other cancers.

Read more
February 16, 2017

Cancer immunotherapies are finally coming of age and represent a new armamentarium in the fight against cancer.

Read more
February 16, 2017

Dr. Graham Pawelec discusses current research on the effect of immunotherapy in older patients with cancer and how it compares with the effect in younger patients. 

Read more
February 16, 2017

ASCO’s Leadership Development and Professional Development Committees are addressing physician burnout in a blog and a pilot “Resiliency Skills Training Initiative.”

Read more
February 16, 2017

Are we at the beginning of an era in which most cancers may be controlled or even cured with immunotherapy; or are we simply at the end of the beginning of this new field of contemporary immunotherapy? 

Read more

February 16, 2017

Pseudoprogression may be associated with mixed responses, which include shrinkage concomitant with increased tumor size or even new lesions appearing elsewhere. Clinicians may struggle with whether to discontinue potentially effective therapy based on a misinterpretation of scan results.

Read more

February 16, 2017

There is a drive to identify potential responders PD-1/PD-L1 through standardized PD-L1 staining techniques, which has led to debates about diagnostic techniques and what should be considered the threshold for a “positive” finding.

Read more